Stratus Medical raises $10 million Series B to complete development of new technology and fund clinical trial

Stratus Medical完成1000万美元B轮融资，用于新技术的开发和临床试验的资金支持。

MAGNOLIA, Texas, February 4, 2026-- Stratus® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies.

德克萨斯州麦格诺利亚，2026年2月4日——Stratus® Medical是一家专注于推进慢性疼痛射频（RF）消融治疗的公司，宣布完成1000万美元的B轮融资。本轮融资由专注于医疗保健的投资公司Wasatch Health Partners领投，该公司致力于成长型股权投资和中低端市场收购策略。

Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform..

瓦萨奇健康合作伙伴通过其增长基金进行了投资，并且之前通过其结构化资本平台提供了2500万美元的可转换债务融资。

The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis™ basivertebral nerve ablation (BVNA) technology, expand and protect the company's valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS® RF Multitined Expandable Electrode (Nimbus) design..

B轮融资的收益将用于完成Stratus Medical射频发生器和神经血管™基椎神经消融（BVNA）技术的开发，扩充并保护公司宝贵的专利组合，并资助一项临床研究。这些高潜力的技术将使Stratus Medical能够更好地服务其快速增长的客户群，同时利用经过验证且已获专利的NIMBUS®射频多针可扩展电极（Nimbus）设计。

Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain..

椎源性下背痛是指脊柱中的椎体终板因长期退化而受损所引发的疼痛。目前的治疗选择包括药物、物理治疗和椎基神经消融术 (BVNA)。据估计，美国有超过五百万人患有椎源性背痛。

The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.

Stratus Medical射频发生器和neurovasis BVNA技术正在开发中，尚未提交FDA审批、评估或获得FDA批准。

Luke Larsen, Vice President at Wasatch Health Partners, said, 'We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.'.

卢克·拉森，瓦萨奇健康合作伙伴公司的副总裁表示：“我们很高兴能与斯特拉图斯医疗公司扩大合作关系。该公司展现了强大的执行力、持续的收入增长，并在技术开发和临床项目方面取得了显著进展。我们相信，管理团队有能力在此基础上继续发展。”

Bret Boudousquie, CEO of Stratus Medical, commented, 'We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.'.

斯特拉图斯医疗公司首席执行官布雷特·布杜斯基评论道：“我们珍视与瓦萨奇健康合作伙伴的长期合作关系，感谢他们始终支持我们通过推进射频技术来帮助慢性疼痛患者的使命。斯特拉图斯医疗公司很荣幸能与优秀的医生、医院和手术中心合作，我们渴望通过这笔融资所支持的未来射频技术实现更大的价值。”

Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, 'I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement.

俄克拉荷马州临床放射学介入放射科主任Doug Beall医学博士评论道：“我从2020年开始使用Nimbus进行射频消融疼痛治疗，原因是其消融区域更大且易于使用。2022年，我开始为神经血管项目提供科学意见。2024年，我和同事们发表了第一篇科学文章，描述了利用CT重建评估设备放置的神经血管BVNA技术。

This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.'.

该技术基于Nimbus多刺设计，有望为医院和ASC提供更快、更易使用的射频治疗，并降低成本。

About Stratus Medical

关于Stratus医疗

Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal.

Stratus Medical是一家医疗设备公司，专注于通过创新减少疼痛并提高慢性疼痛患者的生活质量。该公司因其收入增长和创新能力获得了德勤技术快速500强、佩珀代因最具资金实力公司以及《休斯顿商业杂志》的认可。

Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas..

基于易用性、缩短的手术时间以及旨在提供持续疼痛缓解的大体积病灶，Nimbus迅速在美国和其他国家获得了市场份额。Stratus Medical总部位于德克萨斯州的麦格诺利亚。

About Wasatch Health Partners

关于瓦萨奇健康合作伙伴

Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah..

瓦萨奇健康合作伙伴是一家专注于医疗保健的投资公司，通过成长型股权投资、中低端市场收购和结构性资本策略，投资于医疗器械、生命科学、外包医疗技术和制药服务公司。该公司总部位于犹他州盐湖城。

Contact:

联系：

Media Contact

媒体联系人

Cody Jorgensen

科迪·约根森

Marketing Communications

营销传播

Stratus Medical

Stratus Medical

346-703-0642

346-703-0642

cody@stratusmedical.com

cody@stratusmedical.com

https://stratusmedical.com

https://stratusmedical.com